Compare
Sign Up

Compare/Updated Oct 26, 2026, refreshed every trading day

IBB vs XBI

iShares Biotechnology ETF against State Street SPDR S&P Biotech ETF: 4 years of returns, risk and today’s technical read, from Kavout’s own data.

IBBiShares Biotechnology ETF
$1,618
+61.8% since Oct 28, 2022
$207.74 today-0.9%
XBIState Street SPDR S&P Biotech ETF
$1,797
+79.7% since Oct 28, 2022
$149.54 today-1.4%
Growth of $1,000adjusted closes, dividends included
$743$1,082$1,420$1,759$2,0982023202420252026IBB $1,618XBI $1,797
IBBXBI1000 trading days, Kavout market data
The short answer

XBI did better over the period: $1,000 invested on October 28, 2022 grew to $1,797, versus $1,618 for IBB, producing total returns of 79.7% and 61.8%, respectively. XBI also led over three years, 119.7% versus 75.0%, and over the past year, 39.9% versus 35.2%. The trade-off was higher risk: XBI’s 12-month volatility was 29.0% versus 22.7% for IBB, and its worst drawdown was -33.0% versus -24.8%. XBI’s 0.35% expense ratio was lower than IBB’s 0.44%, but XBI’s stronger performance came with greater fluctuations and deeper losses. The funds remained highly correlated, at 0.898 over the comparison period and 0.919 over the last 12 months, though IBB moved only 0.65% for each 1% move in XBI.

IBBiShares Biotechnology ETF
$207.74-0.9% today
  • Price is above its 200-day average ($184); 50-day at $208.
  • RSI 52, neutral. Supertrend says sell. ADX 11, so the trend is weak.
DMI Bearish CrossSupertrend BearishStoch RSI OverboughtUnderperforming the market (SPY)OBV Falling
XBIState Street SPDR S&P Biotech ETF
$149.54-1.4% today
  • Price is above its 200-day average ($141); 50-day at $157.
  • RSI 45, neutral. Supertrend says sell. ADX 16, so the trend is weak.
Supertrend BearishStoch RSI OverboughtUnderperforming the market (SPY)OBV Falling

Head to head

Which has returned more, IBB or XBI?

IBB beat XBI in 23 of the last 48 months; XBI won the other 25. The typical monthly gap was 2.20 points.

Total return by period

IBBXBI
1 month
-0.7%
-4.2%
3 months
+10.3%
-0.7%
6 months
+22.4%
+12.3%
YTD
+23.2%
+22.8%
1 year
+35.2%
+39.9%
3 years
+75.0%
+119.7%
Since 2022-10
+61.8%
+79.7%

Which is riskier?

Volatility, last 12 months
22.7%
29.0%
Worst drawdown since 2022
-24.8%
-33.0%

IBB: Sep 19, 2024 to Apr 8, 2025; XBI: Nov 8, 2024 to Apr 8, 2025

0.898
correlation of daily moves, 4 years
0.65
IBB move per 1% in XBI
0.919
correlation, last 12 months

Month by month

IBB led 23
XBI led 25

Of the last 48 months. The typical gap was 2.20 points.

When did they diverge?

MonthIBBXBIGap
February 2024+1.8%+12.6%-10.73 pts
March 2023+1.6%-8.0%+9.62 pts
May 2023-3.3%+4.6%-7.88 pts
November 2023+6.4%+14.0%-7.65 pts

Where the numbers come from. 1000 daily adjusted closes per fund from the Kavout market-data API, dividends included. Signals and indicators are Kavout’s own, refreshed nightly. Every figure is calculated from those adjusted closes.

Holdings and fees

What do you actually own with IBB and XBI?

IBB
iShares Biotechnology ETF
Expense ratio
0.44%
Fund assets
$11B
Price
$207.74
0.898
correlation
XBI
State Street SPDR S&P Biotech ETF
Expense ratio
0.35%
Fund assets
$8B
Price
$149.54

Go deeper

Ask InvestGPT which one fits your portfolio.

Eight research agents read your holdings, the overlap and the tax side, then answer in plain words. Free accounts get one report a month.

More comparisons

Find another comparison.

Track both, get told when something changes.

Add IBB and XBI to a watchlist and Kavout emails you when a signal flips or a price target is hit.

Free account, no card